- Home
- LOPE vs LEGN Comparison
LOPE vs LEGN Comparison
Compare LOPE & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOPE | LEGN |
|---|---|---|
| Founded | 1949 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.9B |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LOPE | LEGN |
|---|---|---|
| Price | $157.18 | $27.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $220.00 | $72.92 |
| AVG Volume (30 Days) | 451.7K | ★ 1.8M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.46 | N/A |
| Revenue | ★ $1,090,524,000.00 | $909,045,000.00 |
| Revenue This Year | $9.10 | $68.68 |
| Revenue Next Year | $6.57 | $48.49 |
| P/E Ratio | $20.97 | ★ N/A |
| Revenue Growth | 7.05 | ★ 74.75 |
| 52 Week Low | $153.82 | $25.71 |
| 52 Week High | $223.04 | $45.30 |
Technical Indicators
Market Signals| Indicator | LOPE | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 27.27 | 32.76 |
| Support Level | $154.36 | $25.71 |
| Resistance Level | $160.55 | $29.39 |
| Average True Range (ATR) | 5.00 | 1.47 |
| MACD | 0.11 | -0.24 |
| Stochastic Oscillator | 14.87 | 23.62 |
Price Performance
Historical ComparisonAbout LOPE Grand Canyon Education Inc.
Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges both online, on the ground at its campus in Phoenix, Arizona and at four off-site classroom and laboratory sites. The Company generates all of its revenue through services agreements with its university partners.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.